Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 16, Issue 12, Pages 1239-1249Publisher
INFORMA HEALTHCARE
DOI: 10.1517/14728222.2012.722206
Keywords
cancer; epigenetics; histone demethylase; leukaemia; LSD1; tranylcypromine analogues
Categories
Funding
- Cancer Research UK [C5759/A12328]
Ask authors/readers for more resources
Introduction: The role of epigenetic dysfunction in cancer is increasingly appreciated. This has raised the question as to whether enzymes that regulate the structure and function of chromatin might represent novel therapeutic targets. The histone demethylase LSD1 is one such candidate and novel, potent inhibitors are under development. Areas covered: The literature on LSD1 (also known as KDM1A, AOF2, BHC110 or KIAA0601) was identified in Pubmed and is herein discussed. Areas covered include the structure and enzymatic activity of LSD1, its role in chromatin regulatory complexes, its functional roles in normal and malignant tissue, pharmacological inhibitors of its activity and their putative therapeutic roles. Expert opinion: Pre-clinical data supporting a therapeutic role for LSD1 inhibitors are most encouraging in acute myeloid leukaemia, although optimal dosing strategies and beneficial combinations with other agents remain unclear. Studies making use of potent, selective LSD1 inhibitors active in the nanomolar range are required to establish therapeutic indications in other subtypes of haematological malignancy, and in solid tumours.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available